Solid Biosciences Inc
SLDB6.520USD
+0.290+4.65%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
507.80MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Solid Biosciences Inc Unternehmen
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
Solid Biosciences Inc Informationen
BörsenkürzelSLDB
Name des UnternehmensSolid Biosciences Inc
IPO-datumJan 26, 2018
CEOCumbo (Alexander)
Anzahl der mitarbeiter100
WertpapierartOrdinary Share
GeschäftsjahresendeJan 26
Addresse500 Rutherford Avenue
StadtCHARLESTOWN
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl02129
Telefon16173374680
Websitehttps://www.solidbio.com/
BörsenkürzelSLDB
IPO-datumJan 26, 2018
CEOCumbo (Alexander)
Führungskräfte von Solid Biosciences Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
268.06K
-80258.00%
Mr. Ilan Ganot
Mr. Ilan Ganot
Co-Founder, Director
Co-Founder, Director
133.53K
+3884.00%
Mr. Ian F. Smith, CPA
Mr. Ian F. Smith, CPA
Executive Chairman of the Board
Executive Chairman of the Board
131.26K
+4573.00%
Mr. David Tyronne (Ty) Howton, Jr.
Mr. David Tyronne (Ty) Howton, Jr.
Chief Operating Officer, General Counsel, secretary
Chief Operating Officer, General Counsel, secretary
116.75K
-37771.00%
Mr. Kevin Tan
Mr. Kevin Tan
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
92.38K
-26837.00%
Dr. Jessie Hanrahan, Ph.D.
Dr. Jessie Hanrahan, Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
82.67K
-26535.00%
Mr. Paul Herzich
Mr. Paul Herzich
Chief Technology Officer
Chief Technology Officer
71.12K
-26250.00%
Dr. Sukumar Nagendran, M.D.
Dr. Sukumar Nagendran, M.D.
Independent Director
Independent Director
4.15K
--
Dr. Martin I. Freed, M.D.
Dr. Martin I. Freed, M.D.
Independent Director
Independent Director
3.58K
--
Dr. Clare Kahn, Ph.D.
Dr. Clare Kahn, Ph.D.
Independent Director
Independent Director
2.96K
+1860.00%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
268.06K
-80258.00%
Mr. Ilan Ganot
Mr. Ilan Ganot
Co-Founder, Director
Co-Founder, Director
133.53K
+3884.00%
Mr. Ian F. Smith, CPA
Mr. Ian F. Smith, CPA
Executive Chairman of the Board
Executive Chairman of the Board
131.26K
+4573.00%
Mr. David Tyronne (Ty) Howton, Jr.
Mr. David Tyronne (Ty) Howton, Jr.
Chief Operating Officer, General Counsel, secretary
Chief Operating Officer, General Counsel, secretary
116.75K
-37771.00%
Mr. Kevin Tan
Mr. Kevin Tan
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
92.38K
-26837.00%
Dr. Jessie Hanrahan, Ph.D.
Dr. Jessie Hanrahan, Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
82.67K
-26535.00%
Umsatzaufteilung
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach RegionUSD
Name
Umsatz
Anteil
United States
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Tue, Nov 18
Aktualisiert: Tue, Nov 18
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Perceptive Advisors LLC
15.19%
Bain Capital Life Sciences Investors, LLC
10.15%
Invus Public Equities Advisors, LLC
9.52%
RA Capital Management, LP
7.46%
BlackRock Institutional Trust Company, N.A.
5.21%
Andere
52.47%
Aktionäre
Aktionäre
Anteil
Perceptive Advisors LLC
15.19%
Bain Capital Life Sciences Investors, LLC
10.15%
Invus Public Equities Advisors, LLC
9.52%
RA Capital Management, LP
7.46%
BlackRock Institutional Trust Company, N.A.
5.21%
Andere
52.47%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
38.87%
Hedge Fund
23.54%
Investment Advisor/Hedge Fund
18.48%
Private Equity
15.19%
Venture Capital
7.46%
Research Firm
2.38%
Individual Investor
1.13%
Bank and Trust
0.13%
Pension Fund
0.07%
Institutionelle Beteiligung
Aktualisiert: Mon, Jan 5
Aktualisiert: Mon, Jan 5
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
257
82.72M
106.17%
-17.41M
2025Q3
245
82.26M
105.58%
-6.26M
2025Q2
237
81.08M
104.59%
+27.37M
2025Q1
237
79.86M
103.02%
+25.88M
2024Q4
198
36.85M
67.00%
-4.80M
2024Q3
199
36.30M
93.97%
-4.52M
2024Q2
188
37.99M
98.93%
-1.65M
2024Q1
182
35.35M
93.37%
+4.46M
2023Q4
181
16.93M
83.83%
-1.01M
2023Q3
190
16.39M
81.73%
-2.06M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Perceptive Advisors LLC
11.83M
15.19%
-73.11K
-0.61%
Sep 30, 2025
Bain Capital Life Sciences Investors, LLC
7.91M
10.15%
--
--
Sep 30, 2025
Invus Public Equities Advisors, LLC
7.42M
9.52%
--
--
Sep 30, 2025
RA Capital Management, LP
5.81M
7.46%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
4.06M
5.21%
-309.31K
-7.08%
Sep 30, 2025
Adage Capital Management, L.P.
4.00M
5.13%
-2.73M
-40.56%
Sep 30, 2025
The Vanguard Group, Inc.
3.08M
3.96%
-281.70K
-8.37%
Sep 30, 2025
Vestal Point Capital, LP
2.98M
3.82%
+1.47M
+97.67%
Sep 30, 2025
Fidelity Management & Research Company LLC
2.91M
3.74%
-264.27K
-8.31%
Sep 30, 2025
Citadel Advisors LLC
2.59M
3.33%
+69.40K
+2.75%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Tue, Dec 2
Aktualisiert: Tue, Dec 2
Name
Anteil
iShares Neuroscience and Healthcare ETF
0.52%
iShares Micro-Cap ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares Biotechnology ETF
0.03%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Mehr Anzeigen
iShares Neuroscience and Healthcare ETF
Anteil0.52%
iShares Micro-Cap ETF
Anteil0.06%
ProShares Ultra Nasdaq Biotechnology
Anteil0.04%
Invesco Nasdaq Biotechnology ETF
Anteil0.04%
iShares Biotechnology ETF
Anteil0.03%
Invesco RAFI US 1500 Small-Mid ETF
Anteil0.02%
iShares Russell 2000 Value ETF
Anteil0.02%
Avantis US Small Cap Equity ETF
Anteil0.02%
iShares Russell 2000 ETF
Anteil0.01%
ProShares UltraPro Russell2000
Anteil0.01%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
Datum
Ex-Dividendentag
Art
Verhältnis
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
Oct 27, 2022
Merger
15→1
